Skip to main content

Salmon calcitonin in the acute management of hypercalcemia

Calcified Tissue International volume 46, pages S26–S30 (1990)Cite this article

Summary

Salmon calcitonin has been used for the management of acute hypercalcemia for the past several years. Unlike other hypocalcemic agents, it is effective within 2 hours after first dosing. This pharmacologic agent shows peak effect at 24–48 hours and has a duration of action of 4–7 days in most cases. Its effectiveness may diminish thereafter despite continuous administration (the so-called “escape phenomenon”). Salmon calcitonin has been shown to be effective in the management of acute hypercalcemia due to a variety of causes, and, because of its low toxicity profile, it may be administered to patients with congestive heart failure or azotemia. Salmon calcitonin is also an analgesic agent in patients with pain associated with bone metastases and may be used in conjunction with other hypocalcemic agents such as mithramycin, the bisphosphonates, or gallium nitrate to prolong the clinical response to more than 1 week. Salmon calcitonin is therefore effective and safe in the management of acute hypercalcemia.

This is a preview of subscription content, access via your institution.

Access options

Buy single article

Instant access to the full article PDF.

USD 39.95

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

References

  1. Copp DH, Cameron EC, Cheney BA, et al.: Evidence for calcitonin: a new hormone from the parathyroid that lowers blood calcium.Endocrinology 1962;70:638–649

    PubMed  CAS  Google Scholar 

  2. Tepperman J:Metabolic and Endocrine Physiology, 3rd ed. Chicago: Year Book Medical Publishers; 1973, pp. 227–229

    Google Scholar 

  3. Talmage RV, Cooper CW, Toverud SU: The physiological significance of calcitonin. In: Peck WA (ed):Bone and Mineral Research, Annual 1. Amsterdam: Excerpta Medica; 1983, pp. 74–143

    Google Scholar 

  4. de Luise M, Martin TJ, Melick RA: Inactivation and degradation of porcine calcitonin by rat liver and relative stability of salmon calcitonin.J Endocrinol 1970;48:181–188

    Google Scholar 

  5. Fillastre JP, Humbert G, Leroy J, Maitrot J, Deshayes P, Canonne MA: Furosemide, mithramycin, and salmon calcitonin in hypercalcemia.Eur J Intensive Care Med 1975;1:185–188

    Article  Google Scholar 

  6. Wisneski LA, Croom WP, Silva OL, Becker KL, et al: Salmon calcitonin in hypercalcemia.Clinical Pharmacol Ther 1978;24:219–222

    CAS  Google Scholar 

  7. Adachi I, Kimura S, Yamaguchi K, Suzuki M, Abe K: Synthetic salmon calcitonin as an antihypercalcemic agent for hypercalcemia in malignancy.Gan To Kaguku Ryoho 1986; 13:2637–2644

    CAS  Google Scholar 

  8. Au WYW: Calcitonin treatment of hypercalcemia due to parathyroid carcinoma: synergistic effect of prednisone on long-term treatment of hypercalcemia.Arch Intern Med 1975;135:1594–1597

    PubMed  Article  CAS  Google Scholar 

  9. Deftos LJ, Neer R: Medical management of the hypercalcemia of malignancy.Ann Rev Med 1974;25:323–330

    PubMed  Article  CAS  Google Scholar 

  10. Stevenson JC: Current management of malignant hypercalcemia.Drugs 1988;36:229–239

    PubMed  CAS  Google Scholar 

  11. Caulin F: Personal communication, Rorer International, 1989

  12. Raisz LG, Trummel CL, et al.: Effect of glucocorticoids on bone resorption in tissue culture.Endocrinology 1972;90:961–967

    PubMed  CAS  Article  Google Scholar 

  13. Bilezikian J: Etiologies and therapy of hypercalcemia.Endocrinol Metab Clin North Am 1989;18:408

    Google Scholar 

  14. Binstock MI, Mundy GR: Effect of calcitonin and glucosteroids in combination on the hypercalcemia of malignancy.Ann Intern Med 1980;93:269–271

    PubMed  CAS  Google Scholar 

  15. Ralston SH, Gardner MD, Dryburgh FJ, Jenkins AS, Cowan RA, Boyle IT: Comparison of aminohydroxypropylidene diphosphonate, mithramycin, and corticosteroids/calcitonin in treatment of cancer-associated hypercalcaemia.Lancet 1985;ii:907–910

    Article  Google Scholar 

  16. Ralston SH, Alzaid AA, Gardner MD, Boyle IT: Treatment of cancer-associated hypercalcaemia with combined aminohydroxypropylidene diphosphonate and calcitonin.Br Med J 1986;292:1549–1550

    CAS  Article  Google Scholar 

  17. Junghall S, Rastad J, Akerstrom G: Comparative effects of calcitonin and clodronate in hypercalcaemia.Bone 1987;8 (Suppl. 1):S79-S83

    Google Scholar 

  18. Warrell RP, et al.: Gallium nitrate for acute treatment of cancer-related hypercalcemia: clinicopharmacological and dose-response analysis.Cancer Res 1986;46:4208–4212

    PubMed  Google Scholar 

  19. Warrell RP, Israel R, Frisone M, Snyder T, Gaynor JJ, Bockman RS: Gallium nitrate for acute treatment of cancer-related hypercalcemia: a randomized double-blind comparison to calcitonin.Ann Intern Med 1988;108(5):669–674

    PubMed  Google Scholar 

  20. Thiebaud D, Burckhardt P, Jaeger P, Azria M: Effectiveness of salmon calcitonin administered as suppositories in tumor-induced hypercalcemia.Am J Med 1987;82(4):745–750

    PubMed  Article  CAS  Google Scholar 

  21. Wallach S: Treatment of Paget's disease. In:Advances in Internal Medicine, Vol. 27. Chicago, Year Book Medical Publishers, 1982; pp. 1–43

    Google Scholar 

  22. Hamilton Jr CR: Effects of synthetic salmon calcitonin in patients with Paget's disease of bone.Am J Med 1974;56: 315–322

    PubMed  Article  Google Scholar 

  23. Silva OL, Becker KL: Salmon calcitonin in the treatment of hypercalcemia.Arch Intern Med 1973;132:337–339

    PubMed  Article  CAS  Google Scholar 

  24. Hindley AC, Hill EB, Leyland MJ, Wiles AE: A double-blind controlled trial of salmon calcitonin in pain due to malignancy.Cancer Chemother Pharmacol 1982;9:71–74

    PubMed  Article  CAS  Google Scholar 

  25. Gennari C, Chierichetti SM, Piolini M, Vibelli C, Agnusdei D, Civitelli R, et al.: Analgesic activity of salmon and human calcitonin against cancer pain: a double-blind, placebo-controlled clinical study.Curr Ther Res 1985;38:298–308

    Google Scholar 

  26. Szanto J, Jozsef S, Rado J, Juhos E, Hindy I, Eckhardt S: Pain killing with calcitonin in patients with malignant tumours.Oncology 1986;43:69–72

    PubMed  CAS  Article  Google Scholar 

  27. Roth A, Kolaric K: Analgesic activity of calcitonin in patients with painful osteolytic metastases of breast cancer.Oncology 1986;43:283–287

    PubMed  CAS  Article  Google Scholar 

  28. Serdengecti S, Serdengecti K, Derman U, Berkarda B: Salmon calcitonin in the treatment of bone metastases.Int J Clin Pharm Res 1986;6:151–155

    CAS  Google Scholar 

  29. Schiraldi GF, Soresi E, Locicero S, Harari S, Scoccia S: Salmon calcitonin in cancer pain: comparison between two different treatment schedules.Int J Clin Pharmacol Ther Toxicol 1987;25:229–232

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medicine, George Washington University Medical Center, Washington, DC, USA

    Leonard A. Wisneski

Authors
  1. Leonard A. Wisneski
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Wisneski, L.A. Salmon calcitonin in the acute management of hypercalcemia. Calcif Tissue Int 46, S26–S30 (1990). https://doi.org/10.1007/BF02553290

Download citation

  • Received:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02553290

Keywords

  • Calcitonin
  • Hypercalcemia
  • Serum Calcium Level
  • Parathyroid Carcinoma
  • Salmon Calcitonin